NEW YORK, Dec. 21 /PRNewswire/ -- Paul Capital Healthcare today announced that it has led an investment to provide more than $100 million to UCB S.A. in exchange for certain payments relating to the sales of products marketed by third parties.

UCB announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.

The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.

Press release: regulated information UCB announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat(TM), for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.

* Results in proof of concept trial encourage further analysis * Promising side effect profile observed UCB announced today headline results based on first-line analyses of its Phase IIa clinical trial with lacosamide to treat fibromyalgia syndrome.